Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China
· Delayed Price · Currency is CNY 57.27
-0.73 (-1.26%)
Jun 4, 2025, 2:45 PM CST
SHA:688621 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Net Income | 134.23 | 177.41 | 184.76 | 156.47 | 105.66 | 72.46 | Upgrade
|
| Depreciation & Amortization | 48.33 | 48.33 | 43.5 | 38.83 | 27.47 | 9.61 | Upgrade
|
| Other Amortization | 20.16 | 20.16 | 20.48 | 14.01 | 5.91 | 5.23 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | 0.04 | -0 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.31 | 0.31 | 0.71 | 0.21 | 0.52 | 0.08 | Upgrade
|
| Loss (Gain) From Sale of Investments | 1.82 | 1.82 | -1.29 | -2.62 | -1.68 | -0.42 | Upgrade
|
| Provision & Write-off of Bad Debts | 41.68 | 41.68 | 57.77 | 18.66 | 10.47 | 3.06 | Upgrade
|
| Other Operating Activities | 57.62 | 10.31 | 12.68 | 10.64 | 5.12 | 2.32 | Upgrade
|
| Change in Accounts Receivable | -326.37 | -326.37 | -250.51 | -151.92 | -143.04 | -35.13 | Upgrade
|
| Change in Inventory | -0.64 | -0.64 | -1.87 | -4.7 | -1.55 | -2.55 | Upgrade
|
| Change in Accounts Payable | 70.22 | 70.22 | 48.77 | 36.05 | 81.74 | 8.65 | Upgrade
|
| Change in Other Net Operating Assets | 12.98 | 12.98 | - | - | - | - | Upgrade
|
| Operating Cash Flow | 36.15 | 32.02 | 92.86 | 103.96 | 88.25 | 62.99 | Upgrade
|
| Operating Cash Flow Growth | -80.17% | -65.52% | -10.67% | 17.80% | 40.09% | 10.57% | Upgrade
|
| Capital Expenditures | -16.53 | -30.48 | -72.96 | -103.87 | -84.96 | -27.03 | Upgrade
|
| Sale of Property, Plant & Equipment | -0.01 | - | 0 | 0 | 0 | - | Upgrade
|
| Cash Acquisitions | 96 | - | - | - | - | -4 | Upgrade
|
| Investment in Securities | -71 | -40 | -17 | 89.75 | -192.51 | -5.09 | Upgrade
|
| Other Investing Activities | 28.39 | 27.86 | 1.29 | 2.62 | 1.68 | 0.42 | Upgrade
|
| Investing Cash Flow | 36.85 | -42.63 | -88.66 | -11.5 | -275.78 | -35.7 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 216.17 | 148.01 | 37 | Upgrade
|
| Long-Term Debt Issued | - | 431.15 | 393.49 | - | - | - | Upgrade
|
| Total Debt Issued | 484.97 | 431.15 | 393.49 | 216.17 | 148.01 | 37 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -153.01 | -33.5 | -25.5 | Upgrade
|
| Long-Term Debt Repaid | - | -439.6 | -237.61 | -11.72 | -16.19 | -1.5 | Upgrade
|
| Total Debt Repaid | -477.88 | -439.6 | -237.61 | -164.72 | -49.69 | -27 | Upgrade
|
| Net Debt Issued (Repaid) | 7.09 | -8.44 | 155.88 | 51.45 | 98.32 | 10 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 487.55 | - | Upgrade
|
| Common Dividends Paid | -37.48 | -38.15 | -55.52 | -26.98 | -1.25 | -1.07 | Upgrade
|
| Other Financing Activities | -184.19 | -81.14 | -22.56 | 1.75 | -16.15 | -3.4 | Upgrade
|
| Financing Cash Flow | -214.58 | -127.74 | 77.8 | 26.22 | 568.48 | 5.52 | Upgrade
|
| Net Cash Flow | -141.57 | -138.35 | 82 | 118.68 | 380.95 | 32.82 | Upgrade
|
| Free Cash Flow | 19.62 | 1.54 | 19.9 | 0.09 | 3.29 | 35.96 | Upgrade
|
| Free Cash Flow Growth | -83.95% | -92.28% | 21552.67% | -97.21% | -90.84% | 14.89% | Upgrade
|
| Free Cash Flow Margin | 1.86% | 0.14% | 2.14% | 0.01% | 0.67% | 10.35% | Upgrade
|
| Free Cash Flow Per Share | 0.17 | 0.01 | 0.18 | 0.00 | 0.03 | 0.43 | Upgrade
|
| Cash Income Tax Paid | 70.49 | 65.46 | 41.24 | 32.8 | 12.06 | 17.45 | Upgrade
|
| Levered Free Cash Flow | -8.12 | -54.66 | -53.26 | -49.86 | -26.78 | 3.66 | Upgrade
|
| Unlevered Free Cash Flow | 1.38 | -44.59 | -45.65 | -43.79 | -24.55 | 4.31 | Upgrade
|
| Change in Net Working Capital | 128.84 | 192.8 | 157.59 | 90.35 | 47.96 | 34.85 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.